Shares of Vermillion, Inc. (NASDAQ:VRML) have earned an average broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.
Analysts have set a 12-month consensus price target of $2.25 for the company, according to Zacks. Zacks has also assigned Vermillion an industry rank of 80 out of 255 based on the ratings given to related companies.
Separately, ValuEngine raised Vermillion from a “hold” rating to a “buy” rating in a research note on Friday, July 6th.
In other Vermillion news, CFO Robert Harry Beechey bought 100,000 shares of the stock in a transaction on Tuesday, August 14th. The shares were bought at an average price of $0.52 per share, with a total value of $52,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Valerie Barber Palmieri bought 97,000 shares of the stock in a transaction on Friday, August 17th. The shares were acquired at an average cost of $0.52 per share, for a total transaction of $50,440.00. Following the purchase, the chief executive officer now owns 178,063 shares in the company, valued at $92,592.76. The disclosure for this purchase can be found here. In the last three months, insiders purchased 291,100 shares of company stock worth $157,931 and sold 33,473 shares worth $16,837. Company insiders own 4.25% of the company’s stock.
A hedge fund recently raised its stake in Vermillion stock. Lincoln National Corp raised its holdings in shares of Vermillion, Inc. (NASDAQ:VRML) by 331.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,461 shares of the company’s stock after acquiring an additional 99,461 shares during the quarter. Lincoln National Corp owned approximately 0.18% of Vermillion worth $101,000 at the end of the most recent quarter. 26.70% of the stock is owned by institutional investors.
VRML traded down $0.01 during trading on Friday, reaching $0.56. The company had a trading volume of 55,400 shares, compared to its average volume of 125,684. Vermillion has a 12-month low of $0.47 and a 12-month high of $2.10. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.74 and a quick ratio of 5.70.
Vermillion (NASDAQ:VRML) last issued its quarterly earnings results on Thursday, August 9th. The company reported ($0.04) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.04). The firm had revenue of $0.71 million for the quarter. Vermillion had a negative return on equity of 201.03% and a negative net margin of 398.14%.
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
Recommended Story: The Role of a Fiduciary and Individual Investors
Get a free copy of the Zacks research report on Vermillion (VRML)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.